Experiencia en el tratamiento de gliomas de alto grado con temozolomida

• Autores: B. Matilla Fernández, P. González Pérez, Ángel Rodríguez Sánchez, Carmen Villares García
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 7, Nº. 3, 2005, págs. 189-197
• Idioma: español
• Títulos paralelos:
  • Experience in the treatment of high-grade gliomas with temozolomide
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To evaluate the chemotherapeutic treatment and the average survival of patients diagnosed with malignant glioma and treated with temozolomide for three years. Method: Malignant gliomas (anaplastic astrocytoma and multiform glioblastoma) are the most common and aggressive primary brain tumors. These are highly malignant, extensively infiltrating and the highest cause for morbility/mortality in spite of the therapeutic resources being available. Currently, temozolomide is the drug available for their treatment. In this retrospective study, there were included 15 men and 5 women with an average age of 51 years and with a proven histologic diagnose of malignant glioma, who had been previously treated with surgery and radiotherapy. The used temozolomide dose was 150 mg/m 2 for five days, during the first cycle, and, depending on a good tolerance level, it was increased to 200 mg/m 2 every 28 days in later cycles, until progression or toxicity. Results: The average treatment duration was of 6 months and the median of survival since the diagnose was of 11.5 months. Temozolomide was well tolerated, with low toxicity. Conclusions: Temozolomide, administered as a standard pattern at these dosages, is a good therapeutic option, with a predictable safety profile, important benefits in quality of living and increase in average survival for patients with malignant gliomas